Assisted reproductive technology market seen reaching $73.04 billion by 2035

Market Research Future projects the global assisted reproductive technology market will grow from $32.60 billion in 2025 to $73.04 billion by 2035, driven by rising infertility, wider reimbursement, and faster adoption of embryo-selection and cryopreservation tools. North America leads the market now, while Asia-Pacific is expanding on the back of policy support and broader access.

Why it matters: - Rising infertility rates, delayed parenthood, and broader coverage are turning assisted reproductive technology from a niche service into a mainstream healthcare category. - The market’s growth depends on who pays for treatment, making employer benefits and public reimbursement central to access and revenue. - Laboratory technology improvements are changing clinic economics by increasing success rates and making frozen-cycle models more viable.

What happened: - Market Research Future projected the global assisted reproductive technology market will rise from USD 32.60 billion in 2025 to USD 73.04 billion by 2035. - The forecast implies an 8.4% compound annual growth rate from 2026 to 2035. - The market is expected to reach USD 35.34 billion in 2026, the first year of the forecast period. - The report pointed to infertility prevalence, employer benefit expansion, and reimbursement policy as the main growth drivers.

The details: - The World Health Organization estimates roughly one in six adults experiences infertility at some point. - OECD data show mean maternal age at first birth is above 29 in most member states, with Italy, Spain and Korea above 31. - China’s National Healthcare Security Administration extended provincial insurance reimbursement to 17 assisted conception items, beginning in Beijing in July 2023, and the policy has since been replicated across more than 20 provinces. - Kaiser Family Foundation’s 2024 employer survey found 47% of U.S. firms with 200 or more workers cover in-vitro fertilization, up sharply from 2020. - Israel’s state-funded model covers treatment to two live births and supports the world’s highest per-capita cycle rate. - Vitrification survival rates above 95% made freeze-all cycles viable, while freeze-all helped make single-embryo transfer more defensible. - HFEA reported that frozen cycles overtook fresh cycles in the U.K. in 2022. - Technologies shaping treatment include vitrification, blastocyst culture, elective freeze-all cycles, time-lapse incubators and AI-scored morphokinetics. - CooperSurgical is estimated to hold an 11% to 14% revenue share and has the broadest end-to-end laboratory portfolio across media, incubators, witnessing and genetic testing. - Vitrolife Group is estimated to hold a 9% to 12% share through culture media and time-lapse systems. - Merck KGaA and Ferring Pharmaceuticals have jointly committed more than USD 400 million to fertility research and development and manufacturing capacity between 2023 and 2025.

Between the lines: - The report suggests payer design, not clinical capability, is the main constraint in many markets. - Employer-sponsored fertility benefits are helping shift more cycles into contracted centers of excellence, especially in North America. - Consolidation is reshaping the clinic side as private equity and strategic buyers combine single-site practices into larger platforms. - Consolidated groups can negotiate lower consumable prices, standardize protocols and publish comparable outcomes, which strengthens payer contracting. - Consumables and recurring lab spend matter more than one-time equipment sales because they travel with every cycle. - The market’s structure favors vendors that control the full laboratory workflow rather than only capital equipment.

What's next: - North America remains the largest regional market, with 34.0% of global revenue in 2025, or about USD 11.08 billion. - Europe was valued at USD 9.62 billion in 2025, or 29.5% of the market. - Asia-Pacific is expanding on state reimbursement rollouts and rising healthcare access, especially in China and Japan. - South America and the Middle East and Africa remain smaller but growing, with the UAE, Saudi Arabia and Israel highlighted as important regional markets. - The report flagged future opportunity in sub-USD 3,000 cycle models, AI-assisted embryo selection, fertility preservation, cross-border care corridors and clinic platform software. - Market Research Future expects leadership by 2035 to go to the company that can industrialize embryo processing at laboratory scale.

The bottom line: - Assisted reproductive technology is moving toward a larger, more industrialized and more insurance-backed market, with growth tied to access, lab automation and recurring-cycle economics.